SurModics IVD Breakthrough Stabilizer Addresses Industry Challenge
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 29, 2013--
SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc.
(NASDAQ:SRDX) and a market leader for in
vitro diagnostic assay components, is launching its new StabilZyme®
Protein-Free Stabilizer today at the American Association for
Clinical Chemistry (AACC) meeting in Houston.
“This newest addition to SurModics’ stabilization line is significant
for assay developers because it helps even their most sensitive assays
function optimally,” says Gary Maharaj, CEO and president. “Assay
developers have been asking for a top performing, protein-free
stabilizer that addresses their growing needs in the areas of
sensitivity, specificity and reliability.”
Assays have become increasingly sensitive in recent years. However, the
protein stabilizers most commonly used to stabilize biomolecule activity
may contribute to interference and cross-reactivity. SurModics’ new StabilZyme
Protein-Free Stabilizer delivers excellent retained activity—a key
performance factor—while eliminating the risk of interference and
SurModics IVD offers a full range of innovative solutions, including
custom formulations, for the in vitro diagnostics industry. To
learn more, please visit us at AACC (Booth No. 1434), visit our website (www.surmodics.com),
or contact customer service (952-500-7200 or firstname.lastname@example.org).
More than 900 IVD products are available for online ordering at http://shop.surmodics.com.
SurModics and StabilZyme are registered trademarks of
About SurModics, Inc.
SurModics' mission is to exceed our
customers' expectations and enhance the wellbeing of patients by
providing the world's foremost, innovative surface modification
technologies and in vitro diagnostic chemical components. The
Company partners with the world's leading and emerging medical device,
diagnostic and life science companies to develop and commercialize
innovative products designed to improve patient diagnosis and treatment.
Core offerings include (i) surface modification coating technologies
that impart lubricity, prohealing, and biocompatibility capabilities,
and (ii) components for in vitro diagnostic tests and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For
more information about the Company, visit http://www.surmodics.com.
The content of SurModics' website is not part of this release or part of
any filings the Company makes with the SEC.
Source: SurModics, Inc.
Andy LaFrence, 952-500-7000
Finance and Chief Financial Officer